PURPOSE: Recently, familial paraganglioma (PGL) was shown to be caused bymutations in the gene encoding succinate dehydrogenase subunit D (SDHD). However, the prevalence of SDHD mutations in apparently sporadic PGL is unknown. We studied the frequency and spectrum of germ-line and somatic SDHD mutations in patients with parasympathetic PGL. EXPERIMENTAL DESIGH: We studied 57 unselected patients who developed parasympathetic PGLs (n = 105 tumors) and who were treated between 1987 and 1999 at the Erasmus MC (Rotterdam, the Netherlands). Thirty-eight (67%) of these patients (n = 51 tumors) lacked a family history of parasympathetic PGL. We used conformation-dependent gel electrophoresis and sequence determination analysis of germ-line and tumor DNA to identify SDHD mutations. We compared the clinical and molecular characteristics of sporadic and hereditary PGLs. RESULTS: Three different SDHD germ-line mutations were identified in 32 of the 57 (56%) patients. These included 19 of 19 (100%) patients with familial PGL and also 13 of 38 (34%) patients with apparently sporadic PGL. All three mutations were characterized as missense mutations (D92Y, L95P, and L139P) in highly conserved regions of the SDHD gene and were not observed in 200 control alleles. No somatic mutations were found. CONCLUSIONS: Germ-line mutations of the SDHD gene are present in a significant number of patients with apparently sporadic parasympathetic PGL. Somatic SDHD mutations do not play a significant role in the sporadic form of this tumor. Genetic testing for SDHD germ-line mutations should be considered for every patient presenting with this tumor, even if a personal or family history of PGL is absent, to allow appropriate clinical management.
PURPOSE: Recently, familial paraganglioma (PGL) was shown to be caused bymutations in the gene encoding succinate dehydrogenase subunit D (SDHD). However, the prevalence of SDHD mutations in apparently sporadic PGL is unknown. We studied the frequency and spectrum of germ-line and somatic SDHD mutations in patients with parasympathetic PGL. EXPERIMENTAL DESIGH: We studied 57 unselected patients who developed parasympathetic PGLs (n = 105 tumors) and who were treated between 1987 and 1999 at the Erasmus MC (Rotterdam, the Netherlands). Thirty-eight (67%) of these patients (n = 51 tumors) lacked a family history of parasympathetic PGL. We used conformation-dependent gel electrophoresis and sequence determination analysis of germ-line and tumor DNA to identify SDHD mutations. We compared the clinical and molecular characteristics of sporadic and hereditary PGLs. RESULTS: Three different SDHD germ-line mutations were identified in 32 of the 57 (56%) patients. These included 19 of 19 (100%) patients with familial PGL and also 13 of 38 (34%) patients with apparently sporadic PGL. All three mutations were characterized as missense mutations (D92Y, L95P, and L139P) in highly conserved regions of the SDHD gene and were not observed in 200 control alleles. No somatic mutations were found. CONCLUSIONS: Germ-line mutations of the SDHD gene are present in a significant number of patients with apparently sporadic parasympathetic PGL. Somatic SDHD mutations do not play a significant role in the sporadic form of this tumor. Genetic testing for SDHD germ-line mutations should be considered for every patient presenting with this tumor, even if a personal or family history of PGL is absent, to allow appropriate clinical management.
Authors: Dorian R A Swarts; Sandra M H Claessen; Yvonne M H Jonkers; Robert-Jan van Suylen; Anne-Marie C Dingemans; Wouter W de Herder; Ronald R de Krijger; Egbert F Smit; Frederik B J M Thunnissen; Cornelis A Seldenrijk; Aryan Vink; Aurel Perren; Frans C S Ramaekers; Ernst-Jan M Speel Journal: Am J Pathol Date: 2011-07-16 Impact factor: 4.307
Authors: Mariola Peczkowska; Zoran Erlic; Michael M Hoffmann; Mariusz Furmanek; Jaroslaw Cwikla; Agata Kubaszek; Aleksander Prejbisz; Zbigniew Szutkowski; Andrzej Kawecki; Krzysztof Chojnowski; Anna Lewczuk; Mieczyslaw Litwin; Witold Szyfter; Martin A Walter; Maren Sullivan; Charis Eng; Andrzej Januszewicz; Hartmut P H Neumann Journal: J Clin Endocrinol Metab Date: 2008-09-30 Impact factor: 5.958
Authors: Hilde Dannenberg; Paul Komminoth; Winand N M Dinjens; Ernst Jan M Speel; Ronald R de Krijger Journal: Endocr Pathol Date: 2003 Impact factor: 3.943
Authors: Francien H van Nederveen; José Gaal; Judith Favier; Esther Korpershoek; Rogier A Oldenburg; Elly M C A de Bruyn; Hein F B M Sleddens; Pieter Derkx; Julie Rivière; Hilde Dannenberg; Bart-Jeroen Petri; Paul Komminoth; Karel Pacak; Wim C J Hop; Patrick J Pollard; Massimo Mannelli; Jean-Pierre Bayley; Aurel Perren; Stephan Niemann; Albert A Verhofstad; Adriaan P de Bruïne; Eamonn R Maher; Frédérique Tissier; Tchao Méatchi; Cécile Badoual; Jérôme Bertherat; Laurence Amar; Despoina Alataki; Eric Van Marck; Francesco Ferrau; Jerney François; Wouter W de Herder; Mark-Paul F M Vrancken Peeters; Anne van Linge; Jacques W M Lenders; Anne-Paule Gimenez-Roqueplo; Ronald R de Krijger; Winand N M Dinjens Journal: Lancet Oncol Date: 2009-07-01 Impact factor: 41.316
Authors: Kristin Astrom; Joel E Cohen; Joan E Willett-Brozick; Christopher E Aston; Bora E Baysal Journal: Hum Genet Date: 2003-06-17 Impact factor: 4.132
Authors: Jean-Pierre Bayley; Ivonne van Minderhout; Marjan M Weiss; Jeroen C Jansen; Peter H N Oomen; Fred H Menko; Barbara Pasini; Barbara Ferrando; Nora Wong; Lesley C Alpert; Rosie Williams; Edward Blair; Peter Devilee; Peter E M Taschner Journal: BMC Med Genet Date: 2006-01-11 Impact factor: 2.103